Impact of Nonalcoholic Hepatic Steatosis on the Warranty Period of a Coronary Artery Calcium Score of 0: Results From the Multi-Ethnic Study of Atherosclerosis.
Article in Circulation. Cardiovascular imaging, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
10 authors.
Keishi IchikawaLundquist Institute, Harbor-UCLA Medical Center, Torrance, CA (K.I., S.S., S. Krishnan, T.B., S. Kianoush, J.A.-B., V.S.M., M.J.B.).ORCID 0000-0003-0657-514X
Jaewon LimDepartment of Biostatistics, University of Washington, Seattle (J.L., R.L.M.).ORCID 0000-0002-4677-3805
Robyn L McClellandDepartment of Biostatistics, University of Washington, Seattle (J.L., R.L.M.).ORCID 0000-0002-2433-1512
Shriraj SusarlaLundquist Institute, Harbor-UCLA Medical Center, Torrance, CA (K.I., S.S., S. Krishnan, T.B., S. Kianoush, J.A.-B., V.S.M., M.J.B.).ORCID 0000-0001-5697-2675
Srikanth KrishnanLundquist Institute, Harbor-UCLA Medical Center, Torrance, CA (K.I., S.S., S. Krishnan, T.B., S. Kianoush, J.A.-B., V.S.M., M.J.B.).
Travis BenzingLundquist Institute, Harbor-UCLA Medical Center, Torrance, CA (K.I., S.S., S. Krishnan, T.B., S. Kianoush, J.A.-B., V.S.M., M.J.B.).
Sina KianoushLundquist Institute, Harbor-UCLA Medical Center, Torrance, CA (K.I., S.S., S. Krishnan, T.B., S. Kianoush, J.A.-B., V.S.M., M.J.B.).ORCID 0000-0001-7617-2042
Jairo Aldana-BitarLundquist Institute, Harbor-UCLA Medical Center, Torrance, CA (K.I., S.S., S. Krishnan, T.B., S. Kianoush, J.A.-B., V.S.M., M.J.B.).ORCID 0000-0002-9407-7484
Venkat S ManuboluLundquist Institute, Harbor-UCLA Medical Center, Torrance, CA (K.I., S.S., S. Krishnan, T.B., S. Kianoush, J.A.-B., V.S.M., M.J.B.).ORCID 0000-0002-6251-1987
Matthew J BudoffLundquist Institute, Harbor-UCLA Medical Center, Torrance, CA (K.I., S.S., S. Krishnan, T.B., S. Kianoush, J.A.-B., V.S.M., M.J.B.).ORCID 0000-0002-9616-1946
Funding
Institute for Clinical and Translational ResearchUL1TR001079 · NCATS · JOHNS HOPKINS UNIVERSITY · PI FORD, DANIEL ERNEST · 2013 to 2017
$60.1M
Wake Forest Clinical and Translational Science AwardUL1TR001420 · NCATS · WAKE FOREST UNIVERSITY HEALTH SCIENCES · PI ARD, JAMY D, FOLEY, KRISTIE L · 2015 to 2023
$32.3M
Clinical and Translational Science AwardUL1TR000040 · NCATS · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI GINSBERG, HENRY N · 2012 to 2015
$26.2M
Task Area A Core Study Operations.Task Area A shall encompass annual follow-up of cohort members, clinical endpoints ascertainment, study coordination activities, maintenance of the database and biosp75N92020D00001 · NHLBI · UNIVERSITY OF WASHINGTON · PI MCCLELLAND, ROBYN LEAGH · 2020 to 2025
$17.2M
Task Area A shall encompass annual follow-up of cohort members, clinical events investigations, study operations, and data analysis and manuscript writing. If implemented, Task A.1 will provide fundin75N92020D00005 · NHLBI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI WATSON, KAROL E · 2020 to 2025
$5.1M
TO EXERCISE OPTION PERIOD ONE (1) FOR TASK AREA A - MESA CORE OPERATIONS, FIELD CENTER.75N92020D00004 · NHLBI · NORTHWESTERN UNIVERSITY · PI SIEGEL, JONATHAN H · 2020 to 2025
$4.5M
Task Area A shall encompass annual follow-up of cohort members, clinical events investigations, study operations, and data analysis and manuscript writing. If implemented, Task A.1 will provide fundin75N92020D00006 · NHLBI · UNIVERSITY OF MINNESOTA · PI PANKOW, JAMES S · 2020 to 2025
$4.4M
Task Area A shall encompass annual follow-up of cohort members, clinical events investigations, study operations, and data analysis and manuscript writing. If implemented, Task A.1 will provide fundin75N92020D00003 · NHLBI · JOHNS HOPKINS UNIVERSITY · PI POST, WENDY S · 2020 to 2025
$3.8M
Task Area A shall encompass annual follow-up of cohort members, clinical events investigations, study operations, and data analysis and manuscript writing. If implemented, Task A.1 will provide fundin75N92020D00007 · NHLBI · WAKE FOREST UNIVERSITY HEALTH SCIENCES · PI BERTONI, ALAIN GERALD · 2020 to 2025
$3.5M
Task Area A shall encompass annual follow-up of cohort members, clinical events investigations, study operations, and data analysis and manuscript writing. If implemented, Task A.1 will provide fundin75N92020D00002 · NHLBI · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI SHEA, STEVEN J · 2020 to 2025
$3.4M
Coronary Artery Calcium, Aortic Calcification and Density in MESAR01HL146666 · NHLBI · LUNDQUIST INSTITUTE FOR BIOMEDICAL INNOVATION AT HARBOR-UCLA MEDICAL CENTER · PI BUDOFF, MATTHEW J · 2020 to 2023
$3.0M
Ventricular Size and Valve Calcification Measures by CTR01HL071739 · NHLBI · LUNDQUIST INSTITUTE FOR BIOMEDICAL INNOVATION AT HARBOR-UCLA MEDICAL CENTER · PI BUDOFF, MATTHEW J · 2003 to 2010
backgroundFor individuals with a coronary artery calcium (CAC) score of 0, CAC rescans at appropriate timings are recommended, depending on individual risk profiles. Although nonalcoholic fatty liver disease, recently redefined as metabolic-associated fatty liver disease, is a risk factor for atherosclerotic cardiovascular disease events, its relationship with the warranty period of a CAC score of 0 has not been elucidated.
methodsA total of 1944 subjects from the MESA (Multi-Ethnic Study of Atherosclerosis) with a baseline CAC score of 0, presence or absence of nonalcoholic hepatic steatosis, and at least 1 follow-up computed tomography scan were included. Nonalcoholic hepatic steatosis was defined using nonenhanced computed tomography and liver/spleen attenuation ratio <1. The association between nonalcoholic hepatic steatosis and new CAC incidence (CAC score >0) was evaluated using a Weibull survival model.
resultsNonalcoholic hepatic steatosis was identified in 268 (14%) participants. Participants with nonalcoholic hepatic steatosis had higher CAC incidence than those without nonalcoholic hepatic steatosis. Nonalcoholic hepatic steatosis was independently associated with new CAC incidence after adjustment for atherosclerotic cardiovascular disease risk factors (hazard ratio, 1.28 [95% CI, 1.05-1.57];
conclusionsNonalcoholic hepatic steatosis had an impact on the warranty period of a CAC score of 0. The study suggests that the time period until a CAC rescan should be shorter in those with nonalcoholic hepatic steatosis and a CAC score of 0.
Indexed as
Coronary Artery DiseaseNon-alcoholic Fatty Liver DiseaseVascular CalcificationAgedAged, 80 and overComputed Tomography AngiographyCoronary AngiographyCoronary VesselsFemaleHumansIncidenceMaleMiddle AgedPredictive Value of TestsProspective StudiesRisk Assessmentatherosclerotic cardiovascular diseasecomputed tomographycoronary artery calciumfatty liver diseaserisk assessment
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Impact of Nonalcoholic Hepatic Steatosis on the Warranty Period of a Coronary Artery Calcium Score of 0: Results From the Multi-Ethnic Study of Atherosclerosis. · full record | OpenQuestion